Cobiprostone
As of the edition of 20 October 2026, Cobiprostone is a small molecule: stopped in 2016; acts on CLCN2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2016
- Kind
- Small molecule
- Registered trials
- 3, 2 stopped early
- Disease areas
- Bones, joints and muscles; Digestive system; Immune system; Mouth and teeth; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Cobiprostone.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CLCN2 | Chloride channel protein 2 | P51788 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 1 | 0 | 2 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Byk-Mallinckrodt CIL | Lead sponsor of trials | 2007 to now |